GOLD2024

Fred Hutchinson Cancer Center

aka Fred Hutch   |   SEATTLE, WA   |  http://www.fredhutch.org/en.html
GuideStar Charity Check

Fred Hutchinson Cancer Center

EIN: 91-1935159


Mission

Fred Hutchinson Cancer Center unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. We’re driven by the urgency of our patients, the hope of our community and our passion for discovery to pursue scientific breakthroughs and healthier lives for every person in every community.

Notes from the nonprofit

Fred Hutch has worked at the front lines of science for nearly five decades. Our early work in bone marrow transplantation led to cures for some types of cancer and offered the first proof that the immune system can stop others. Our researchers continue to make discoveries that improve lives and advance the science of cancer and infectious disease. Now, we’re bringing research and care closer together to speed scientific breakthroughs, advance standards of care, and build the foundation of healthier lives for people in every community. Support from our community makes it possible.

Ruling year info

2000

President and Director, Raisbeck Endowed Chairholder

Thomas J. Lynch Jr. M.D.

Main address

1100 Fairview Ave N P.O. Box 19024

SEATTLE, WA 98109 USA

Show more contact info

Formerly known as

Fred Hutchinson Cancer Research Center

Seattle Cancer Care Alliance

EIN

91-1935159

Subject area info

Specialty hospital care

Public health

Oncology

HIV/AIDS

Infectious and parasitic diseases

Show more subject areas

Population served info

Adults

NTEE code info

Hospital (Specialty) (E24)

What we aim to solve

SOURCE: Self-reported by organization

Fred Hutch has worked at the front lines of science for nearly five decades. Our early work in bone marrow transplantation led to cures for some types of cancer and offered the first proof that the immune system can stop others. Our researchers continue to make discoveries that improve lives and advance the science of cancer and infectious disease. Now, we’re bringing research and care closer together to speed scientific breakthroughs, advance standards of care and build the foundation of healthier lives for people in every community.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Clinical Care

Fred Hutchinson Cancer Center unites comprehensive care and advanced research to provide the latest cancer treatment options and accelerate discoveries that prevent, treat, and defeat cancer and infectious diseases worldwide. While Fred Hutch is an independent, nonprofit organization, it also serves as the cancer program for UW Medicine. This relationship allows for enhanced care coordination with one of the worlds leading integrated health systems. Our clinical program serves more than 50,000 patients annually and has been recognized as the top cancer hospital in Washington for 15 years by U.S. News & World Report. We combine innovative research with exceptional, state-of-the-art patient-centered care. Based in Seattles South Lake Union neighborhood, Fred Hutch also operates eight clinical care sites in the greater Puget Sound region, encompassing hematology/medical oncology, radiation oncology, and infusion services.

Population(s) Served
Adults

Fred Hutch is tackling cancer and other diseases from every angle in our state-of-the-art research labs and in collaborative projects that span the globe. Our more than 245 research faculty members and their teams study more than 40 diseases, generating new discoveries and translating them into effective prevention, detection, and treatment strategies.

Our research program includes six scientific divisions: Basic Science, Clinical Research, Human Biology, Public Health Sciences, Translational Science and Therapeutics, and Vaccine and Infectious Disease. Research areas range from behavioral research and biostatistics to cell biology, gene therapy, and the human microbiome. Our staff are at the forefront of cancer and infectious disease research, epidemiology, and global health. In addition, we are expanding our leadership in immunotherapy, data science, and precision oncology to reduce risk and bring more cures within reach.

Population(s) Served
Adults

Where we work

Awards

E Donnall Thomas, MD 1990

Nobel Prize in Physiology or Medicine

Lee Hartwell, PhD 2001

Nobel Prize in Physiology or Medicine

Linda Buck, PhD 2004

Nobel Prize in Physiology or Medicine

MacArthur Fellow: Mark Roth, PhD 2007

MacArthur Foundation

E Donnall Thomas, MD 1982

National Academy of Sciences

Harold Weintraub, PhD 1986

National Academy of Sciences

Lee Hartwell, PhD 1987

National Academy of Sciences

Bob Eisenman, PhD 1998

National Academy of Sciences

Mark Groudine, MD, PhD 2001

National Academy of Sciences

Linda Buck, PhD 2003

National Academy of Sciences

Steve Henikoff, PhD 2005

National Academy of Sciences

Dan Gottschling, PhD 2011

National Academy of Sciences

Sue Biggins, PhD 2015

National Academy of Sciences

James Priess, PhD 2017

National Academy of Sciences

MacArthur Fellow: Trevor Bedford, PhD 2021

MacArthur Foundation

Harmit Malik, PhD 2019

National Academy of Sciences

Julie Overbaugh, PhD 2021

National Academy of Sciences

Jenn Adair, PhD 2021

Uganda National Academy of Sciences

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Fred Hutchinson Cancer Center unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. We’re driven by the urgency of our patients, the hope of our community and our passion for discovery to pursue scientific breakthroughs and healthier lives for every person in every community.

This is a significant moment for breakthroughs in cancer and infectious disease treatment, care, and cures. Fred Hutch is harnessing this momentum to improve and save lives. Our strategy includes:

Leading in scientific discovery: We will continue to deliver breakthrough research on fundamental science by expanding and diversifying our faculty and researchers; driving forward new understandings about the relationship between cancers, the bodies in which they arise, and the pathogens (such as viruses and bacteria) that may be responsible for as much as one-third of all human cancers. We are also harnessing the power of large data sets to drive scientific discoveries and innovation.

Promoting science that drives clinical innovation: Fred Hutch is working at the forefront of precision oncology, which looks at a person’s individual cancer, and at their unique health and history, to create customized cancer treatments and risk-reduction strategies. We are also advancing new innovations in vaccine development and infectious diseases and digging deeply into how cancer begins — and how it can be prevented.
Developing and testing innovative immunotherapy and cellular therapies. Our scientists are working to develop new cellular, antibody, and combinatorial therapies for cancer and move them to patients as quickly as possible through “bench-to-bedside” research and clinical trials. We are also working to better understand advanced disease and develop better treatments for patients.

Delivering compassionate clinical care and better outcomes for people diagnosed with cancer: Fred Hutch provides best-in-class treatments and care. We are expanding on this excellence to continue to attract and serve patients not just in our region, but around our country and world.

Advancing organizational excellence: We will continue to provide world-class research and excellence in clinical infrastructure and operations. An important part of this work is our commitment to placing diversity, equity and inclusion at the forefront of all we do.

Fred Hutchinson Cancer Center unites comprehensive care and advanced research to provide the latest cancer treatment options and accelerate discoveries that prevent, treat, and defeat cancer and infectious diseases worldwide. Fred Hutch is home to five scientific divisions, eight clinical care sites, and more than 5,700 staff. Our 16-acre Seattle campus includes state-of-the-art laboratories, clinical care facilities, and core facilities that provide services and access to specialized equipment available to all faculty. Our clinical program serves more than 50,000 patients annually and has been recognized as the top cancer hospital in Washington for 15 years by U.S. News & World Report. We also provide wide-ranging education and training programs to develop scientists at all academic levels, from early high school through early career.

Fred Hutch is an independent, nonprofit organization that also serves as the cancer program for UW Medicine. This relationship allows for enhanced care coordination with one of the world’s leading integrated health systems. We are also part of the Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium. Formed in 2002, the Consortium is recognized as an NCI-designated Comprehensive Cancer Center — the only one in Washington. And from Uganda to South Africa to China and beyond, we’re collaborating with research partners to develop new ways to diagnose, predict, prevent and treat cancer around the world.

Fred Hutch has earned a global reputation for discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines. Our more than 245 faculty study more than 40 diseases, and our teams have conducted research in over 70 countries. Our roster of internationally acclaimed scientists includes three Nobel laureates, two MacArthur Fellows, and more than a dozen members of the National Academy of Sciences.
In all our work, we are guided by our values of collaboration, compassion, determination, excellence, innovation, integrity and respect. These are grounded in and expressed through the principles of diversity, equity, and inclusion (DEI).

Fred Hutch is proud to consistently be among the top recipients of research funding from the National Institutes of Health. We also grow and diversify funding from industry partners and work with government agencies, leaders, and policymakers to maintain and grow support for research. This includes accelerating our commercialization impact by increasing the speed and scale with which we bring our specialized knowledge and technology to commercial markets.

In addition, we rely on strong support from a global community of more than 31,000 individual donors. Their support allows us to do all we can, as quickly as we can, to improve and save lives.

Fred Hutch has been advancing prevention, diagnosis, treatments, care, and cures for cancer and infectious diseases for nearly 50 years. Our track record includes advances in bone marrow transplantation, HIV/AIDS prevention, immunotherapy, and COVID-19 vaccines.

Our work in bone marrow and blood stem cell transplantation in the 1970s opened new doors for treatment and offered the first proof the immune system can be harnessed to attack cancer. Today, more than 1.5 million potentially lifesaving bone marrow transplants have been performed worldwide, and Fred Hutch continues to harness the power of the immune system through a world-leading immunotherapy program. Fred Hutch researchers also established the groundwork for the HPV vaccine, which prevents cervical cancer.

We are the global home for the HIV Vaccine Trails Network, the largest publicly funded international collaboration conducting clinical trials of HIV vaccines. Our Bezos Family Immunotherapy Clinic, opened in 2016, is a first-of-its-kind resource that has more than doubled our capacity to serve patients with leukemias and other cancers.

Since the first days of the COVID-19 pandemic, Fred Hutch experts have drawn on extensive experience with HIV, as well as the impact of infectious diseases on cancer patients, to track, study, and monitor the virus. We also coordinated the large-scale trials that brought vaccines to millions in record time.

What’s next: In 2022, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance merged to form Fred Hutchinson Cancer Center, an independent organization that also serves as UW Medicine’s cancer program. This unified structure is bringing research and care closer together and holds significant promise for people diagnosed with cancer and for the future of cancer research. Our priorities include:

* Immunotherapy: Discovering cures for solid tumors by building upon our research in immunotherapies for blood cancers.
* Precision oncology: Making personalized treatments and cures available to everyone diagnosed with cancer through new technologies that identify new targets for therapy.
* Viruses and vaccines: Advancing the detection, prevention, and treatment of HIV, COVID-19, HSV, Epstein-Barr virus, and other viruses, and developing preventive and curative vaccines for cancer and other diseases.
* Data science: Uncovering better treatments through data-driven approaches, such as machine learning and deep analysis of data sets, while harnessing the technological prowess the Pacific Northwest is known for.
* Prevention and early detection: Pinpointing individuals at greatest risk for cancer; finding ways to intervene and prevent it; and, when that is not possible, detecting cancer at an early stage.
* Health disparities: Increasing prevention, screening, early diagnosis, and care in communities disproportionately affected by cancer; enhancing the diversity of our faculty; and ensuring better representation in clinical trials.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We shared information about our current feedback practices.
  • How is your organization using feedback from the people you serve?

  • Which of the following feedback practices does your organization routinely carry out?

  • What challenges does the organization face when collecting feedback?

Financials

Fred Hutchinson Cancer Center
Fiscal year: Jul 01 - Jun 30

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
NET GAIN/LOSS:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022 info

SOURCE: IRS Form 990

0.78

Average of 2.05 over 10 years

Months of cash in 2022 info

SOURCE: IRS Form 990

4

Average of 1.9 over 10 years

Fringe rate in 2022 info

SOURCE: IRS Form 990

28%

Average of 27% over 10 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

Fred Hutchinson Cancer Center

Revenue & expenses

Fiscal Year: Jul 01 - Jun 30

SOURCE: IRS Form 990 info

Fiscal year ending: cloud_download Download Data

Fred Hutchinson Cancer Center

Balance sheet

Fiscal Year: Jul 01 - Jun 30

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data

Fred Hutchinson Cancer Center

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jul 01 - Jun 30

SOURCE: IRS Form 990 info

This snapshot of Fred Hutchinson Cancer Center’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2018 2019 2020 2021 2022
Unrestricted surplus (deficit) before depreciation $71,618,707 $94,062,604 $96,973,824 $179,312,076 $4,344,043
As % of expenses 12.2% 14.2% 13.6% 22.0% 0.4%
Unrestricted surplus (deficit) after depreciation $49,232,127 $70,451,659 $73,875,603 $151,476,031 -$32,181,503
As % of expenses 8.1% 10.3% 10.0% 18.0% -2.8%
Revenue composition info
Total revenue (unrestricted & restricted) $653,487,789 $757,282,570 $820,892,125 $940,996,725 $1,283,961,922
Total revenue, % change over prior year 17.5% 15.9% 8.4% 14.6% 36.4%
Program services revenue 98.0% 96.9% 95.6% 97.5% 81.5%
Membership dues 0.0% 0.0% 0.0% 0.0% 0.0%
Investment income 1.4% 1.8% 1.6% 1.2% 1.6%
Government grants 0.0% 0.0% 1.8% 0.4% 11.1%
All other grants and contributions 0.6% 0.7% 0.8% 0.3% 1.3%
Other revenue 0.0% 0.6% 0.3% 0.6% 4.5%
Expense composition info
Total expenses before depreciation $587,967,366 $660,712,564 $712,555,438 $813,508,821 $1,098,003,883
Total expenses, % change over prior year 16.1% 12.4% 7.8% 14.2% 35.0%
Personnel 25.9% 25.2% 25.2% 24.9% 29.9%
Professional fees 25.8% 23.4% 22.4% 20.4% 18.3%
Occupancy 2.6% 2.3% 3.1% 2.9% 2.8%
Interest 0.6% 0.5% 0.5% 0.5% 0.8%
Pass-through 0.3% 0.5% 0.4% 0.3% 3.2%
All other expenses 44.8% 48.1% 48.4% 51.0% 45.0%
Full cost components (estimated) info 2018 2019 2020 2021 2022
Total expenses (after depreciation) $610,353,946 $684,323,509 $735,653,659 $841,344,866 $1,134,529,429
One month of savings $48,997,281 $55,059,380 $59,379,620 $67,792,402 $91,500,324
Debt principal payment $3,600,225 $3,765,023 $3,814,933 $0 $0
Fixed asset additions $35,161,069 $41,252,177 $52,859,323 $109,696,883 $561,868,082
Total full costs (estimated) $698,112,521 $784,400,089 $851,707,535 $1,018,834,151 $1,787,897,835

Capital structure indicators

Liquidity info 2018 2019 2020 2021 2022
Months of cash 1.3 1.5 2.9 3.5 4.0
Months of cash and investments 7.9 7.8 8.7 12.4 14.7
Months of estimated liquid unrestricted net assets 8.9 8.8 8.8 11.5 8.1
Balance sheet composition info 2018 2019 2020 2021 2022
Cash $64,380,327 $81,139,103 $170,501,135 $236,768,730 $367,961,879
Investments $323,224,639 $346,718,309 $343,196,385 $602,628,545 $979,977,227
Receivables $79,384,161 $120,356,289 $107,797,289 $154,802,509 $424,225,650
Gross land, buildings, equipment (LBE) $306,464,836 $336,687,685 $386,607,522 $491,942,899 $1,292,937,364
Accumulated depreciation (as a % of LBE) 51.0% 50.2% 48.9% 43.2% 37.8%
Liabilities (as a % of assets) 24.4% 25.3% 37.5% 48.6% 68.3%
Unrestricted net assets $482,032,194 $552,483,853 $626,359,456 $777,835,487 $745,653,984
Temporarily restricted net assets $4,581,701 $6,436,738 N/A N/A N/A
Permanently restricted net assets $3,295,589 $3,445,589 N/A N/A N/A
Total restricted net assets $7,877,290 $9,882,327 $10,891,863 $11,646,213 $204,595,000
Total net assets $489,909,484 $562,366,180 $637,251,319 $789,481,700 $950,248,984

Key data checks

Key data checks info 2018 2019 2020 2021 2022
Material data errors No No No No No

Operations

The people, governance practices, and partners that make the organization tick.

Documents
Letter of Determination is not available for this organization
Form 1023/1024 is not available for this organization

President and Director, Raisbeck Endowed Chairholder

Thomas J. Lynch Jr. M.D.

Dr. Thomas J. Lynch Jr. is a world-renowned scientist, highly respected oncologist and successful leader of National Cancer Institute-Designated Comprehensive Cancer Centers. Dr. Lynch sets the strategic direction of the center, oversees center wide initiatives and represents the Hutch’s interests to major partners and governmental bodies. He also directs the Fred Hutch/University of Washington Cancer Consortium and is principal investigator of its Cancer Center Support Grant.

Number of employees

Source: IRS Form 990

Fred Hutchinson Cancer Center

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation
Other
Related
Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization

Fred Hutchinson Cancer Center

Highest paid employees

SOURCE: IRS Form 990

Compensation
Other
Related
Show data for fiscal year
Compensation data
Download up to 5 most recent years of highest paid employee data for this organization

Fred Hutchinson Cancer Center

Board of directors
as of 03/18/2024
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Leigh Morgan

Imaginal Leadership Strategies

Kristianne Blake

Kristianne Gates Blake, P.S.

Sean Boyle

Omniva

Nancy Davidson

Fred Hutchinson Cancer Center

Stephen Graham

Community Volunteer

Joanne Harrell

Community Volunteer

Thomas Lynch

Fred Hutchinson Cancer Center

Julie Nordstrom

Community Volunteer

Eduardo Peñalver

Seattle University

Timothy H Dellit

UW Medicine

Pete Shimer

Deloitte

Brad Simmons

UW Medicine

Kathy Surace-Smith

NanoString Technologies

Ric Anderson

Washington Holdings

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No

Organizational demographics

SOURCE: Self-reported; last updated 11/14/2022

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Male, Not transgender
Sexual orientation
Decline to state
Disability status
Decline to state

Race & ethnicity

No data

Gender identity

No data

Transgender Identity

No data

Sexual orientation

No data

Disability

No data

Equity strategies

Last updated: 11/21/2022

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data
  • We ask team members to identify racial disparities in their programs and / or portfolios.
  • We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
  • We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
Policies and processes
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We have community representation at the board level, either on the board itself or through a community advisory board.
  • We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.
  • We measure and then disaggregate job satisfaction and retention data by race, function, level, and/or team.
  • We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.

Contractors

Fiscal year ending

Professional fundraisers

Fiscal year ending

SOURCE: IRS Form 990 Schedule G

Solicitation activities
Gross receipts from fundraising
Retained by organization
Paid to fundraiser